The TGA indication for dapagliflozin (Forxiga) has been extended to include treatment of symptomatic heart failure with reduced ejection fraction (HFrEF) in adults as an adjunct to standard of care therapy. The extended indication, beyond patients with diabetes, is largely based on the DAPA-HF trial published last year in the NEJM. The data demonstrated a ...
New approach to HFrEF as dapagliflozin approved
By Mardi Chapman
8 Dec 2020